Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study
- PMID: 30252583
- PMCID: PMC6422519
- DOI: 10.1080/21645515.2018.1522469
Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study
Abstract
The objective of this study was to assess the persistence of antibodies after a single dose of quadrivalent HPV vaccine (4vHPV) and the effect of a dose of nonavalent HPV vaccine (9vHPV) given 3-8 years later. Such data might be of interest in the decision-making process regarding the 2-dose course completion in non-compliant vaccinees in jurisdictions which switched from 4vHPV to 9vHPV. Girls who previously received a single dose of 4vHPV were eligible to participate. Blood specimens were collected just before and one month post-9vHPV administration. The specimens were tested by ELISA for the presence of antibodies to 9 HPV types included in the 9vHPV. Thirty-one girls aged 13-18 years (mean 15.5 years) participated in the study. Pre-9vHPV administration, all participants were seropositive to 4 HPV types included in 4vHPV and 58%-87% were seropositive to the five other HPV types included in the 9vHPV. GMTs were 6.1 AU/ml, 7.7 AU/ml, 20.1 IU/ml and 6.3 IU/ml to HPV6, HPV11, HPV16 and HPV18, respectively. The GMTs for the other five HPV types varied from 1.0 to 2.9 AU/ml. One month post-9vHPV administration all 31 participants were seropositive to all 9 HPV types with a 36.1 to 89.1-fold increase of GMTs. High seropositivity rates observed several years after a single dose of 4vHPV and 100% seropositivity after a dose of 9vHPV suggest that this schedule might be used in non-compliant vaccinees or when switching immunization programs from 4vHPV to 9vHPV.
Keywords: human papillomavirus; mixed schedule; vaccination.
Similar articles
-
Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3. Hum Vaccin Immunother. 2019. PMID: 31017850 Free PMC article. Clinical Trial.
-
Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9. Vaccine. 2018. PMID: 30314913 Free PMC article. Clinical Trial.
-
The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.Hum Vaccin Immunother. 2015;11(3):732-8. doi: 10.1080/21645515.2015.1011570. Hum Vaccin Immunother. 2015. PMID: 25714044 Free PMC article. Clinical Trial.
-
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?Euro Surveill. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. Euro Surveill. 2018. PMID: 30326995 Free PMC article. Review.
-
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.Hum Vaccin Immunother. 2017 Oct 3;13(10):2280-2291. doi: 10.1080/21645515.2017.1346755. Hum Vaccin Immunother. 2017. PMID: 28699820 Free PMC article. Review.
Cited by
-
Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.Hum Vaccin Immunother. 2020 Mar 3;16(3):590-594. doi: 10.1080/21645515.2019.1669413. Epub 2019 Oct 22. Hum Vaccin Immunother. 2020. PMID: 31545130 Free PMC article.
-
Immunogenicity of Alternative Dosing Schedules for HPV Vaccines among Adolescent Girls and Young Women: A Systematic Review and Meta-Analysis.Vaccines (Basel). 2020 Oct 20;8(4):618. doi: 10.3390/vaccines8040618. Vaccines (Basel). 2020. PMID: 33092049 Free PMC article. Review.
-
Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3. Hum Vaccin Immunother. 2019. PMID: 31017850 Free PMC article. Clinical Trial.
-
Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Viruses. 2019 Dec 23;12(1):18. doi: 10.3390/v12010018. Viruses. 2019. PMID: 31877975 Free PMC article. Review.
-
Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study.Lancet Reg Health West Pac. 2025 Feb 20;56:101499. doi: 10.1016/j.lanwpc.2025.101499. eCollection 2025 Mar. Lancet Reg Health West Pac. 2025. PMID: 40061912 Free PMC article.
References
-
- Sabeena S, Bhat PV, Kamath V, Arunkumar G. Global human papilloma virus vaccine implementation: an update. J Obstet Gynaecol Res. 2018. Mars;8: 989–997 . - PubMed
-
- D'Addario M, Redmond S, Scott P, Egli-Gany D, Riveros-Balta AX, Henao Restrepo AM, Low N. Two-dose schedules for human papillomavirus vaccine: systematic review and meta-analysis. Vaccine. 2017. Mai 19;35(22):2892–901. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources